That's literal fake news lol --
https://www.cdc.gov/csels/dls/locs/..._Retirement_CDC_2019_Novel_Coronavirus_1.html
That's the full explanation of withdrawing one specific CDC-made PCR test:
Does the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel confuse influenza with SARS-CoV-2?
No. The CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel does not confuse influenza with SARS-CoV-2. It is a highly accurate test that detects the presence or absence of SARS-CoV-2 viral genetic material within a patient specimen.
Does the retirement of this test apply to all RT-PCR-based tests or all SARS-CoV-2 tests that have received Emergency Use Authorization from FDA?
No. The discontinuation of Emergency Use Authorization (EUA)
only applies to the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel test. It does
not affect any other SARS-CoV-2 test that has received EUA from FDA.
Is CDC retiring the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel because it has produced inaccurate results?
No. There are no performance concerns with this test. The CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel is a highly accurate test. It has been used to successfully detect SARS-CoV-2 since February 2020.
Since the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel continues to perform well, CDC will continue to make the design of the primers and probes used in the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel publicly available on the CDC website. Laboratories and test developers are free to use the design in their own research or diagnostic test.
CDC will also continue to extend Right of Reference to anyone who wishes to reference the data in CDC’s Emergency Use Authorization (EUA 200001) to support their own regulatory submission to FDA. The retirement of the test and the discontinuation of the associated EUA will have no impact on the availability of the design or Right of Reference. The CDC submission will remain on file at FDA.